From: Optimization of combined temozolomide and peptide receptor radionuclide therapy (PRRT) in mice after multimodality molecular imaging studies
Group
Number of mice
Treatment
Imaging
177Lu-TATE
4
50Â MBq 177Lu-TATE i.v.
6 × MRI, 1 × SPECT/CT
TMZ
7
TMZ 50Â mg/kg p.o. for 14Â days
7 × MRI, 7 × SPECT/CT
Control
3
Saline
3 × MRI